Normal view MARC view ISBD view

Metronomic chemotherapy in advanced oral cancers

In Journal of Cancer Research and Therapeutics
By: Patil V.
Contributor(s): Banavali SD | DCruz AK | Noronha V | | Prabhash K.
Material type: materialTypeLabelArticleSeries: Vol 8 Issues 6 Suppl.Publisher: 2012Description: S106-110.Subject(s): Palliative | Oral cavity cancer | Metronomic | Chemotherapy | DDC classification: In: Journal of Cancer Research and TherapeuticsSummary: Context: To assess the feasibility of metronomic chemotherapy in the palliative care setting. Aims: To study the toxicity profile and efficacy of metronomic chemotherapy for palliation in oral cavity cancers. Settings and Design: Retrospective analysis of prospectively collected data. Materials and Methods: Subjects receiving metronomic chemotherapy from August 2010 to January 2011 for palliation in oral cancers subjected to certain criteria were included. Metronomic chemotherapy offered was a combination of twice daily celecoxib 200 mg and weekly methotrexate 15 mg/m 2 .The chemotherapy was continued till disease progression, intolerable side effects or patients' desire to stop. The toxicity profile was reported in accordance with common terminology criteria for adverse events (CTCAE) version 4.02. The efficacy was noted in terms of symptom control, response rates, progression free survival (PFS) and overall survival (OS). Statistical analysis used: SPSS version 16 has been utilized. Descriptive analy
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR12241

Context: To assess the feasibility of metronomic chemotherapy in the palliative care setting.
Aims: To study the toxicity profile and efficacy of metronomic chemotherapy for palliation in oral cavity cancers.
Settings and Design: Retrospective analysis of prospectively collected data.
Materials and Methods: Subjects receiving metronomic chemotherapy from August 2010 to January 2011 for palliation in oral cancers subjected to certain criteria were included. Metronomic chemotherapy offered was a combination of twice daily celecoxib 200 mg and weekly methotrexate 15 mg/m 2 .The chemotherapy was continued till disease progression, intolerable side effects or patients' desire to stop. The toxicity profile was reported in accordance with common terminology criteria for adverse events (CTCAE) version 4.02. The efficacy was noted in terms of symptom control, response rates, progression free survival (PFS) and overall survival (OS).
Statistical analysis used: SPSS version 16 has been utilized. Descriptive analy

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha